Protagonist Therapeutics, Inc. announced the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the United States. Protagonist will receive the $300 million upfront payment associated with the transaction in the second quarter of 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.32 USD | -4.38% | -4.88% | +32.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.49% | 1.86B | |
+63.69% | 62.59B | |
-1.80% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.69% | 26.21B | |
-21.87% | 19.09B | |
+4.24% | 13.08B | |
+25.64% | 12.26B | |
+28.18% | 12.05B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda